3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Nasopharyngeal Carcinoma
7
Melanoma
3
Lung Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Nasopharyngeal Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Esophageal Neoplasms
2
Unresectable Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pleural Effusion, Malignant
1
Osteosarcoma
1
Neuroblastoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Advanced Pancreatic Cancer
1
Advanced Gastric Cancer
1
Advanced Colorectal Cancer
1
Interventions
Oxaliplatin
3
Cetuximab
3
Capecitabine
3
Irinotecan
2
trifluridine tipiracil drug combination
1
surufatinib
1
regorafenib
1
raltitrexed
1
plocabulin
1
nimotuzumab
1
irinotecan sucrosofate
1
endostar protein
1
durvalumab
1
defactinib
1
Panitumumab
1
N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide
1
Drug Therapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Colorectal Cancer
×
endostar protein
×
Clear all
NCT00853684
2009-09-18
OXCE
Shanghai Jiao Tong University School of Medicine
Phase 2
Unknown
44 enrolled